Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

Title: Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

Volume: 1 Issue: 2

Author(s): Punam Sandhu, Paul A. Andrews, Maribeth P. Baker, Kenneth A. Koeplinger, Eric D. Soli, Thomas Miller and Thomas A. Baillie

Affiliation:

Keywords: Vorinostat, histone deacetylases, glucuronidation, β-oxidation, 4-anilino-4-oxobutanoic acid

Abstract: The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.

Cite this article as:

Sandhu Punam, Andrews A. Paul, Baker P. Maribeth, Koeplinger A. Kenneth, Soli D. Eric, Miller Thomas and Baillie A. Thomas, Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species, Drug Metabolism Letters 2007; 1 (2) . https://dx.doi.org/10.2174/187231207780363642